A detailed history of Congress Park Capital LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Congress Park Capital LLC holds 233,800 shares of CTMX stock, worth $303,940. This represents 0.23% of its overall portfolio holdings.

Number of Shares
233,800
Previous 239,300 2.3%
Holding current value
$303,940
Previous $370,000 37.57%
% of portfolio
0.23%
Previous 0.18%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$1.41 - $2.74 $7,755 - $15,070
-5,500 Reduced 2.3%
233,800 $509,000
Q4 2023

Jan 19, 2024

BUY
$1.07 - $1.55 $135,729 - $196,617
126,850 Added 112.81%
239,300 $370,000
Q3 2023

Oct 13, 2023

BUY
$1.26 - $1.87 $7,938 - $11,781
6,300 Added 5.93%
112,450 $145,000
Q2 2023

Jul 13, 2023

BUY
$1.41 - $1.92 $8,389 - $11,424
5,950 Added 5.94%
106,150 $182,000
Q1 2023

Apr 19, 2023

BUY
$1.48 - $2.88 $148,296 - $288,576
100,200 New
100,200 $151,000
Q2 2021

Aug 13, 2021

SELL
$6.33 - $9.91 $127,910 - $200,251
-20,207 Closed
0 $0
Q1 2021

Apr 19, 2021

SELL
$6.6 - $9.0 $36,960 - $50,400
-5,600 Reduced 21.7%
20,207 $156,000
Q4 2020

Jan 19, 2021

SELL
$6.47 - $7.9 $341,318 - $416,756
-52,754 Reduced 67.15%
25,807 $169,000
Q3 2020

Oct 20, 2020

SELL
$6.55 - $8.83 $50,762 - $68,432
-7,750 Reduced 8.98%
78,561 $522,000
Q2 2020

Jul 27, 2020

SELL
$7.4 - $14.64 $91,020 - $180,072
-12,300 Reduced 12.47%
86,311 $719,000
Q1 2020

May 04, 2020

BUY
$3.61 - $8.6 $14,259 - $33,970
3,950 Added 4.17%
98,611 $756,000
Q4 2019

Jan 31, 2020

SELL
$5.17 - $8.91 $378,185 - $651,766
-73,150 Reduced 43.59%
94,661 $787,000
Q3 2019

Oct 24, 2019

SELL
$7.38 - $12.25 $5,904 - $9,800
-800 Reduced 0.47%
167,811 $1.24 Million
Q2 2019

Aug 02, 2019

SELL
$9.35 - $11.41 $401,068 - $489,431
-42,895 Reduced 20.28%
168,611 $1.72 Million
Q1 2019

Apr 18, 2019

BUY
$9.5 - $19.16 $837,852 - $1.69 Million
88,195 Added 71.52%
211,506 $2.27 Million
Q4 2018

Feb 06, 2019

BUY
$12.69 - $18.61 $141,176 - $207,036
11,125 Added 9.92%
123,311 $1.86 Million
Q3 2018

Oct 29, 2018

BUY
$18.04 - $26.41 $48,004 - $70,277
2,661 Added 2.43%
112,186 $2.08 Million
Q2 2018

Aug 06, 2018

BUY
$21.38 - $29.68 $38,484 - $53,424
1,800 Added 1.67%
109,525 $2.5 Million
Q1 2018

Apr 17, 2018

SELL
$21.76 - $34.22 $397,120 - $624,515
-18,250 Reduced 14.49%
107,725 $3.07 Million
Q4 2017

Feb 13, 2018

BUY
$19.0 - $23.09 $2.39 Million - $2.91 Million
125,975
125,975 $2.66 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $85.7M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Congress Park Capital LLC Portfolio

Follow Congress Park Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Congress Park Capital LLC with notifications on news.